Free Trial

Tempest Therapeutics (TPST) Competitors

Tempest Therapeutics logo
$0.92 -0.01 (-0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$0.93 +0.01 (+0.93%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TPST vs. CDTX, IFRX, LXEO, STRO, SLN, ZNTL, ADAP, NKTX, BTAI, and FATE

Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Cidara Therapeutics (CDTX), InflaRx (IFRX), Lexeo Therapeutics (LXEO), Sutro Biopharma (STRO), Silence Therapeutics (SLN), Zentalis Pharmaceuticals (ZNTL), Adaptimmune Therapeutics (ADAP), Nkarta (NKTX), BioXcel Therapeutics (BTAI), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.

Tempest Therapeutics vs.

Tempest Therapeutics (NASDAQ:TPST) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tempest Therapeutics has a beta of -1.69, meaning that its share price is 269% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Tempest Therapeutics presently has a consensus price target of $21.67, suggesting a potential upside of 2,209.88%. Cidara Therapeutics has a consensus price target of $32.20, suggesting a potential upside of 33.06%. Given Tempest Therapeutics' higher possible upside, equities research analysts plainly believe Tempest Therapeutics is more favorable than Cidara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempest Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cidara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.33

Tempest Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -69.64% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tempest TherapeuticsN/A -187.44% -82.61%
Cidara Therapeutics -289.05%-69.64%-33.73%

In the previous week, Cidara Therapeutics had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Cidara Therapeutics and 2 mentions for Tempest Therapeutics. Cidara Therapeutics' average media sentiment score of 0.65 beat Tempest Therapeutics' score of 0.40 indicating that Cidara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tempest Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cidara Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cidara Therapeutics received 351 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 70.36% of users gave Cidara Therapeutics an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote.

CompanyUnderperformOutperform
Tempest TherapeuticsOutperform Votes
100
65.79%
Underperform Votes
52
34.21%
Cidara TherapeuticsOutperform Votes
451
70.36%
Underperform Votes
190
29.64%

Cidara Therapeutics has higher revenue and earnings than Tempest Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempest TherapeuticsN/AN/A-$29.49M-$1.53-0.61
Cidara Therapeutics$63.90M2.67-$22.93M-$25.52-0.95

Summary

Cidara Therapeutics beats Tempest Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TPST vs. The Competition

MetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$40.93M$6.91B$5.77B$9.21B
Dividend YieldN/A2.90%5.27%3.99%
P/E Ratio-0.619.1725.4619.47
Price / SalesN/A324.03472.6678.83
Price / CashN/A75.4646.0638.90
Price / Book0.675.527.325.09
Net Income-$29.49M$123.25M$3.19B$222.54M
7 Day Performance4.56%3.46%3.03%2.74%
1 Month Performance1.33%2.60%4.39%2.11%
1 Year Performance-75.19%1.57%21.93%17.05%

Tempest Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TPST
Tempest Therapeutics
3.1685 of 5 stars
$0.92
-0.6%
$21.67
+2,243.9%
-75.4%$40.34MN/A-0.6020Short Interest ↓
News Coverage
CDTX
Cidara Therapeutics
4.1158 of 5 stars
$21.69
+0.1%
$32.20
+48.4%
+67.4%$152.89M$44.65M-0.8590News Coverage
IFRX
InflaRx
3.5569 of 5 stars
$2.55
+3.3%
$8.00
+213.6%
+29.0%$150.97M$70,000.00-2.3760Short Interest ↓
News Coverage
LXEO
Lexeo Therapeutics
3.338 of 5 stars
$4.56
-7.9%
$23.80
+421.9%
-71.0%$150.80M$650,000.00-1.4458Short Interest ↓
STRO
Sutro Biopharma
4.2805 of 5 stars
$1.83
-8.3%
$11.13
+509.6%
-58.7%$150.49M$153.73M-1.13240
SLN
Silence Therapeutics
2.5262 of 5 stars
$4.93
-1.6%
$54.75
+1,010.3%
-78.2%$149.02M$31.55M-3.17100Short Interest ↑
ZNTL
Zentalis Pharmaceuticals
2.8035 of 5 stars
$2.09
+8.6%
$8.24
+295.4%
-81.3%$148.58MN/A-0.84160Upcoming Earnings
ADAP
Adaptimmune Therapeutics
2.2812 of 5 stars
$0.58
-6.9%
$2.79
+383.1%
-51.8%$147.39M$175.04M-2.62490Short Interest ↑
NKTX
Nkarta
2.7316 of 5 stars
$2.08
-4.4%
$15.00
+622.9%
-79.6%$146.43MN/A-1.10140Analyst Revision
News Coverage
BTAI
BioXcel Therapeutics
4.5213 of 5 stars
$2.93
+11.0%
$37.00
+1,162.8%
-95.9%$146.21M$1.38M-1.3690Gap Up
FATE
Fate Therapeutics
4.2876 of 5 stars
$1.26
-1.2%
$6.75
+437.8%
-81.2%$142.93M$63.53M-0.76550Analyst Revision
News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:TPST) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners